Advanced search
1 file | 1.04 MB

Vaccine options for influenza : thinking small

Bert Schepens (UGent) , Dorien De Vlieger (UGent) and Xavier Saelens (UGent)
Author
Organization
Abstract
Vaccines that direct the immune response towards conserved B cell epitopes of influenza viruses can provide broad protection. In many instances, this requires the design of vaccine antigens that stimulate the immune system to levels that far exceed the natural responses towards such antigens. Here we focus on the matrix protein 2 ectodomain (M2e) as a 'universal' influenza A vaccine candidate. Thanks to its small size and high solubility, M2e can be expressed and delivered in almost any format. Protection against experimental influenza A virus challenge by M2e-based vaccines has been demonstrated in natural host of influenza and clinical studies demonstrated that such vaccines are safe and immunogenic. M2e-specific antibodies protect mainly by Fc receptor-mediated antibody-dependent cellular phagocytosis activity, which is reminiscent to how antibodies directed against the hemagglutinin stalk protect in vivo. Fighting influenza with a broadly protective influenza vaccine will likely require a blend of conserved antigens. M2e deserves its place in such a blend.
Keywords
VIRUS M2 PROTEIN, SOLID-STATE NMR, A-VIRUS, MATRIX PROTEIN-2, EXTRACELLULAR DOMAIN, MONOCLONAL-ANTIBODY, UNIVERSAL VACCINE, IMMUNE-RESPONSES, PROTECTION, CHICKENS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.04 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Schepens, Bert, Dorien De Vlieger, and Xavier Saelens. 2018. “Vaccine Options for Influenza : Thinking Small.” Ed. Patrick C Wilson and Florian Krammer. Current Opinion in Immunology 53: 22–29.
APA
Schepens, B., De Vlieger, D., & Saelens, X. (2018). Vaccine options for influenza : thinking small. (P. C. Wilson & F. Krammer, Eds.)CURRENT OPINION IN IMMUNOLOGY, 53, 22–29.
Vancouver
1.
Schepens B, De Vlieger D, Saelens X. Vaccine options for influenza : thinking small. Wilson PC, Krammer F, editors. CURRENT OPINION IN IMMUNOLOGY. 2018;53:22–9.
MLA
Schepens, Bert, Dorien De Vlieger, and Xavier Saelens. “Vaccine Options for Influenza : Thinking Small.” Ed. Patrick C Wilson & Florian Krammer. CURRENT OPINION IN IMMUNOLOGY 53 (2018): 22–29. Print.
@article{8583901,
  abstract     = {Vaccines that direct the immune response towards conserved B cell epitopes of influenza viruses can provide broad protection. In many instances, this requires the design of vaccine antigens that stimulate the immune system to levels that far exceed the natural responses towards such antigens. Here we focus on the matrix protein 2 ectodomain (M2e) as a 'universal' influenza A vaccine candidate. Thanks to its small size and high solubility, M2e can be expressed and delivered in almost any format. Protection against experimental influenza A virus challenge by M2e-based vaccines has been demonstrated in natural host of influenza and clinical studies demonstrated that such vaccines are safe and immunogenic. M2e-specific antibodies protect mainly by Fc receptor-mediated antibody-dependent cellular phagocytosis activity, which is reminiscent to how antibodies directed against the hemagglutinin stalk protect in vivo. Fighting influenza with a broadly protective influenza vaccine will likely require a blend of conserved antigens. M2e deserves its place in such a blend.},
  author       = {Schepens, Bert and De Vlieger, Dorien and Saelens, Xavier},
  editor       = {Wilson, Patrick C and Krammer, Florian},
  issn         = {0952-7915},
  journal      = {CURRENT OPINION IN IMMUNOLOGY},
  keywords     = {VIRUS M2 PROTEIN,SOLID-STATE NMR,A-VIRUS,MATRIX PROTEIN-2,EXTRACELLULAR DOMAIN,MONOCLONAL-ANTIBODY,UNIVERSAL VACCINE,IMMUNE-RESPONSES,PROTECTION,CHICKENS},
  language     = {eng},
  pages        = {22--29},
  title        = {Vaccine options for influenza : thinking small},
  url          = {http://dx.doi.org/10.1016/j.coi.2018.03.024},
  volume       = {53},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: